Le Lézard
Classified in: Health

RYAH GROUP INC. - Failure-to File Cease Trade Order-Reception of First Comment Letter from the Ontario Securities Commission


TORONTO, Feb. 6, 2023 /CNW/ - RYAH GROUP Inc. (¨RYAH¨- ''the Corporation''-CSE)

RYAH wishes to announce that it has received the First Comment Letter from the Ontario Securities Commission regarding the Failure-to-File Cease Trade Order issued under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocation in Multiple Jurisdictions (the Policy) and RYAH's application for relief from section 144 of the Securities Act (Ontario). The OSC have requested further clarification on the documents submitted to date.

As announced in late July 2022, the Ontario Securities Commission (''OSC'') issued a Failure-to-File Cease Trade Order (''FFCTO'') on the trading of RYAH Group's subordinate voting shares listed on the Canadian Securities Exchange. This FFCTO is still in place.

RYAH management endeavors to address the various comments as soon as possible, and formally respond to the OSC. Management will remain proactive in answering any further queries from the Commission and hopes to obtain the revocation of the FFCTO as soon as possible. RYAH will keep investors updated with regular news releases.

About RYAH Group Inc.:

RYAH is a global Big Data and cannabis and other nutraceutical delivery technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other substances administered through its IoT-connected devices including the world's only Smart InhalerTM and Smart PatchTM.

AI: Artificial Intelligence
IoT: Internet of Things

Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

SOURCE RYAH Group, Inc.


These press releases may also interest you

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...



News published on and distributed by: